Cover Image

Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer

Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided...

Full description

Saved in:
Bibliographic Details
Main Authors: Manzar Alam, Shoaib Alam, Anas Shamsi, Mohd Adnan, Abdelbaset Mohamed Elasbali, Waleed Abu Al-Soud, Mousa Alreshidi, Yousef MohammedRabaa Hawsawi, Anitha Tippana, Pasupuleti Visweswara Rao, Md. Imtaiyaz Hassan
Format: Article
Language:English
English
Published: Frontiers Media SA 2022
Subjects:
RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens
Online Access:https://eprints.ums.edu.my/id/eprint/33339/1/Bax.pdf
https://eprints.ums.edu.my/id/eprint/33339/2/Bax1.pdf
https://eprints.ums.edu.my/id/eprint/33339/
https://www.frontiersin.org/articles/10.3389/fonc.2022.869672/full
http://dx.doi.org/10.3389/fonc.2022.869672
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.ums.eprints.33339
record_format eprints
spelling my.ums.eprints.333392022-07-17T02:27:54Z https://eprints.ums.edu.my/id/eprint/33339/ Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer Manzar Alam Shoaib Alam Anas Shamsi Mohd Adnan Abdelbaset Mohamed Elasbali Waleed Abu Al-Soud Mousa Alreshidi Yousef MohammedRabaa Hawsawi Anitha Tippana Pasupuleti Visweswara Rao Md. Imtaiyaz Hassan RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided the development of numerous antitumor drugs. The development and improvement of rationally planned inhibitors and agents targeting particular cellular and biological pathways in cancer have been signified as a most important paradigm shift in the strategy to treat and manage lung cancer. Newer approaches and novel chemotherapeutic agents are required to accompany present cancer therapies for improving efficiency. Using natural products as a drug with an effective delivery system may benefit therapeutics. Naturally originated compounds such as phytochemicals provide crucial sources for novel agents/drugs and resources for tumor therapy. Applying the small-molecule inhibitors (SMIs)/phytochemicals has led to potent preclinical discoveries in various human tumor preclinical models, including lung cancer. In this review, we summarize recent information on the molecular mechanisms of the Bax/Bcl-2 cascade and EGFR pathway in NSCLC and target them for therapeutic implications. We further described the therapeutic potential of Bax/Bcl-2/EGFR SMIs, mainly those with more potent and selectivity, including gefitinib, EGCG, ABT-737, thymoquinone, quercetin, and venetoclax. In addition, we explained the targeting EGFR pathway and ongoing in vitro and in vivo and clinical investigations in NSCLC. Exploration of such inhibitors facilitates the future treatment and management of NSCLC. Frontiers Media SA 2022-03 Article PeerReviewed text en https://eprints.ums.edu.my/id/eprint/33339/1/Bax.pdf text en https://eprints.ums.edu.my/id/eprint/33339/2/Bax1.pdf Manzar Alam and Shoaib Alam and Anas Shamsi and Mohd Adnan and Abdelbaset Mohamed Elasbali and Waleed Abu Al-Soud and Mousa Alreshidi and Yousef MohammedRabaa Hawsawi and Anitha Tippana and Pasupuleti Visweswara Rao and Md. Imtaiyaz Hassan (2022) Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer. Frontiers in Oncology, 12. pp. 1-24. ISSN 2234-943X https://www.frontiersin.org/articles/10.3389/fonc.2022.869672/full http://dx.doi.org/10.3389/fonc.2022.869672
institution Universiti Malaysia Sabah
building UMS Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaysia Sabah
content_source UMS Institutional Repository
url_provider http://eprints.ums.edu.my/
language English
English
topic RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens
spellingShingle RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens
Manzar Alam
Shoaib Alam
Anas Shamsi
Mohd Adnan
Abdelbaset Mohamed Elasbali
Waleed Abu Al-Soud
Mousa Alreshidi
Yousef MohammedRabaa Hawsawi
Anitha Tippana
Pasupuleti Visweswara Rao
Md. Imtaiyaz Hassan
Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
description Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in NSCLC. Increasing understanding of the molecular mechanisms of fundamental tumor progression has guided the development of numerous antitumor drugs. The development and improvement of rationally planned inhibitors and agents targeting particular cellular and biological pathways in cancer have been signified as a most important paradigm shift in the strategy to treat and manage lung cancer. Newer approaches and novel chemotherapeutic agents are required to accompany present cancer therapies for improving efficiency. Using natural products as a drug with an effective delivery system may benefit therapeutics. Naturally originated compounds such as phytochemicals provide crucial sources for novel agents/drugs and resources for tumor therapy. Applying the small-molecule inhibitors (SMIs)/phytochemicals has led to potent preclinical discoveries in various human tumor preclinical models, including lung cancer. In this review, we summarize recent information on the molecular mechanisms of the Bax/Bcl-2 cascade and EGFR pathway in NSCLC and target them for therapeutic implications. We further described the therapeutic potential of Bax/Bcl-2/EGFR SMIs, mainly those with more potent and selectivity, including gefitinib, EGCG, ABT-737, thymoquinone, quercetin, and venetoclax. In addition, we explained the targeting EGFR pathway and ongoing in vitro and in vivo and clinical investigations in NSCLC. Exploration of such inhibitors facilitates the future treatment and management of NSCLC.
format Article
author Manzar Alam
Shoaib Alam
Anas Shamsi
Mohd Adnan
Abdelbaset Mohamed Elasbali
Waleed Abu Al-Soud
Mousa Alreshidi
Yousef MohammedRabaa Hawsawi
Anitha Tippana
Pasupuleti Visweswara Rao
Md. Imtaiyaz Hassan
author_facet Manzar Alam
Shoaib Alam
Anas Shamsi
Mohd Adnan
Abdelbaset Mohamed Elasbali
Waleed Abu Al-Soud
Mousa Alreshidi
Yousef MohammedRabaa Hawsawi
Anitha Tippana
Pasupuleti Visweswara Rao
Md. Imtaiyaz Hassan
author_sort Manzar Alam
title Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
title_short Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
title_full Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
title_fullStr Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
title_full_unstemmed Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
title_sort bax/bcl-2 cascade is regulated by the egfr pathway: therapeutic targeting of non-small cell lung cancer
publisher Frontiers Media SA
publishDate 2022
url https://eprints.ums.edu.my/id/eprint/33339/1/Bax.pdf
https://eprints.ums.edu.my/id/eprint/33339/2/Bax1.pdf
https://eprints.ums.edu.my/id/eprint/33339/
https://www.frontiersin.org/articles/10.3389/fonc.2022.869672/full
http://dx.doi.org/10.3389/fonc.2022.869672
_version_ 1760231150728511488
score 13.211869

Similar Items